The effect of fixed dose combination of rosuvastatin and ezetimibe on the arterial stiffness
DOI:
https://doi.org/10.34687/2219-8202.JAD.2024.03.0007Abstract
The purpose of this study was to evaluate the effect of fixed dose combination ща rosuvastatin with ezetimibe on lipid levels, C-reactive blood protein and arterial stiffness in individuals with type 2a hyperlipidemia.
Material and methods. The study included 40 subjects, 37 of them completed the course of treatment (59% of women, average age 57±8 years). Before the study and after 12 weeks of taking a fixed combination of rosuvastatin with ezetimibe 20/10 mg, serum levels of total cholesterol, triglycerides, HDL cholesterol, glucose, blood enzymes, C-reactive protein were determined. The content of low-density lipoprotein cholesterol (LDL cholesterol) was calculated using the Friedewald formula. Three methods were used to assess arterial stiffness: ultrasound examination of the carotid arteries, applanation tonometry, and volumetric sphygmography.
Results. Against the background of therapy, a significant decrease in total cholesterol, triglycerides, LDL cholesterol, C-reactive protein, glucose was demonstrated by 41, 25, 56, 38 and 6%, respectively. There were no changes in the parameters of arterial stiffness during ultrasound: the stiffness index β, the coefficients of extensibility and compliance. At the same time, a decrease in arterial stiffness was revealed according to applanation tonometry - carotid-femoral pulse wave velocity decreased from 9.4±1.5 to 9.0±1.1 m/s (p< 0.01) against the background of a significant decrease in blood pressure, while antihypertensive therapy did not change.
Conclusion. As a result of therapy with the fixed dose combination of rosuvastatin with ezetimibe 20/10 mg for 3 months, a significant decrease in low-density lipoprotein cholesterol, C-reactive protein and an improvement in arterial stiffness of the carotid-femoral pulse wave velocity was shown.
Downloads
References
WHO. Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-
(cvds) (дата обращения: 24.06.2024).
Healthcare in Russia 2023: statistical. coll. M.: Rosstat, 2023. P. 179 In Russian. Здравоохранение в России 2023:
статистич. сб. М.: Росстат, 2023. С. 179).
Ezhov MV, Kukharchuk VV, Sergienko IV, Alieva AS, Antsiferov MB, Ansheles AA, et al. Disorders of l i pid metabolism.
Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. In Russian. (Ежов М.В., Кухарчук В.В.,
Сергиенко И.В., Алиева А.С., Анциферов М.Б., Аншелес А.А. и др. Нарушения липидного обмена. Клинические реко-
мендации 2023. Российский кардиологический журнал. 2023;28(5):5471). doi: 10.15829/1560-4071-2023-5471.
Upala S, Wirunsawanya K, Jaruvongvanich V, Sanguankeo A. Effects of statin therapy on arterial stiffness: A
systematic review and meta-analysis of randomized controlled trial. Int J Cardiol. 2017;227:338-341. doi: 10.1016/j.
ijcard.2016.11.073.
Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, et al.; Artery Society; European
Society of Hypertension Working Group on Vascular Structure and Function; European Network for Noninvasive
Investigation of Large Arteries. Expert consensus document on the measurement of aortic stiffness in daily practice
using carotid-femoral pulse wave velocity. J Hypertens. 2012;30(3):445-448. doi: 10.1097/HJH.0b013e32834fa8b0.
Cecelja M, Chowienczyk P. Role of arterial stiffness in cardiovascular disease. JRSM Cardiovasc Dis.
;1(4):cvd.2012.012016. doi: 10.1258/cvd.2012.012016.
Cameron JD, Jennings GL, Dart AM. The relationshi p between arterial compliance, age, blood pressure and serum li pid
levels. J. Hypertens. 1995;13:1718-1723. doi: 10.1097/00004872-199512010-00038.
Kovács B , Cseprekál O , Diószegi Á , Lengyel S , Maroda L , Paragh G , et al. The Importance of Arterial Stiffness
Assessment in Patients with Familial Hypercholesterolemia. J Clin Med. 2022;11(10):2872. doi: 10.3390/jcm11102872.
Boos CJ, Li p GY. Elevated high-sensitive C-reactive protein, large arterial stiffness and atherosclerosis: a relationshi p
between inflammation and hypertension? J Hum Hypertens. 2005;19(7):511-513. doi: 10.1038/sj.jhh.1001858.
Zanoli L. Arterial stiffness is a vascular biomarker of chronic inflammation. Biomark Med. 2019;13(16):1335-1337.
doi: 10.2217/bmm-2019-0394.
Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR, Wilkinson IB. C-reactive protein is associated with
arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol. 2004;24:969-974. doi: 10.1161/01.
ATV.zhq0504.0173.
Cheng HM, Ye ZX, Chiou KR, Lin SJ, Chang MJ. Vascular stiffness in familial hypercholesterolaemia is associated with
C-reactive protein and cholesterol burden. Eur J Clin Investig. 2007;37:197-206. doi: 10.1111/j.1365-2362.2007.01772.x.
Kolmakova TE, Alekseeva IA, Tmoyan NA, Ezhov MV. Combined l i pid-lowering therapy with rosuvastatin and ezetimibe
is the key to success in the treatment and prevention of cardiovascular diseases. Medical advice. 2024;18(5):22-
doi: 10.21518/ms2024-124. In Russian. (Колмакова Т.Е., Алексеева И.А., Тмоян Н.А., Ежов М.В. Комбинированная
гиполипидемическая терапия розувастатином и эзетимибом – залог успеха в лечении и профилактике сер-
дечно-сосудистых заболеваний. Медицинский совет. 2024;18(5):22-29). doi: 10.21518/ms2024-124.
Canepa M, Artom N, Ameri P, Carbone F, Montecucco F, Ghigliotti G, et al. Short-term effect of rosuvastatin treatment
on arterial stiffness in individuals with newly-diagnosed heterozygous familial hypercholesterolemia. Int J
Cardiol. 2018;255:215-220. doi: 10.1016/j.ijcard.2017.12.051.
Mitsiou E, Boutari C, Kotsis V, Georgianou E, Doumas M, Karagiannis A, Athyros VG. Effect of Low (5 mg) vs. High
(20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver
Disease in Patients with Optimally Controlled Arterial Hypertension. Curr Vasc Pharmacol. 2018;16(4):393-400. doi:
2174/1570161115666170630122833
Liu B, Che W, Yan H, Zhu W, Wang H. Effects of rosuvastatin vs. simvastatin/ezetimibe on arterial wall stiffness
in patients with coronary artery disease. Intern Med. 2013;52(24):2715-2719. doi: 10.2169/internalmedicine.52.0731.
Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on
arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588-2605. doi: 10.1093/
eurheartj/ehl254.
Vasyuk YuA, Ivanova SV, Shkolnik EL, Kotovskaya YuV, Milyagin VA, Oleynikov VE, et al. Consensus of Russian experts
on the evaluation of arterial stiffness in clinical practice. Cardiovascular Therapy and Prevention. 2016;15(2):4-19.
In Russian. (Васюк Ю.А., Иванова С.В., Школьник Е.Л., Котовская Ю.В., Милягин В.А., Олейников В.Э. и др. Согласо-
ванное мнение российских экспертов по оценке артериальной жесткости в клинической практике. Кардиоваску-
лярная терапия и профилактика. 2016;15(2);4-19). doi: 10.15829/1728-8800-2016-2-4-19.
Asmar R. Princi ples and usefulness of the cardio-ankle vascular index (CAVI): a new global arterial stiffness
index. Eur Heart J Suppl. 2017;19(Suppl B):B4-B10. doi: 10.1093/eurheartj/suw058.
Saiki A, Watanable Y, Yamaguchi T, Ohira M, Nagayama D, Sato N, et al. CAVI-Lowering Effect of Pitavastatin May
Be Involved in the Prevention of Cardiovascular Disease: Subgroup Analysis of the TOHO-LIP. J Open Access.
;28(10):1083-1094. doi: 10.5551/jat.60343.
Vlachopoulos CH, Terentes-Printzios D, Laurent S, Nilsson PM, Protogerou AD, Aznaouridis K, et al. Association of Estimated
PulseWave Velocity With Survival A Secondary Analysis of SPRINT. JAMA Network Open. 2019;2(10):e1912831.
doi: 10.1001/jamanetworkopen.2019.12831.
Alidadi M, Montecucco F, Jamialahmadi T, Al-Rasadi K, Johnston TP, Sahebkar A. Beneficial Effect of Statin Therapy
on Arterial Stiffness. Biomed Res Int. 2021;2021:5548310. doi: 10.1155/2021/5548310.
Zairova AR, Rogoza AN, Kaminnaya VI, Zubareva MYu, Chubykina UV, Shuvalova YuA, et al. Arterial stiffness in
patients with atherosclerosis and dysl i pidemia on the background of drug therapy as a possible marker of residual
risk. Atherosclerosis and dysli pidemia. 2022;3(48):29-40. In Russian. (Заирова А.Р., Рогоза А.Н., Каминная В.И.,
Зубарева М.Ю., Чубыкина У.В., Шувалова Ю.А. и др. Артериальная жесткость у больных с атеросклерозом и
дислипидемией на фоне медикаментозной терапии как возможный маркер резидуального риска. Атеросклероз и
дислипидемии. 2022;3(48):29-40). doi: 10.34687/2219-8202.JAD.2022.03.0004.
Matsushita K, Ding N, Kim ED, Budoff M, Chirinos JA, Fernhall B, et al. Cardio-ankle vascular index and
cardiovascular disease: Systematic review and meta-analysis of prospective and cross-sectional studies. J Clin
Hypertens (Greenwich). 2019;21(1):16-24. doi: 10.1111/jch.13425.
Zairova AR, Rogoza AN, Oshchepkova EV, Yarovaya EB, Kutsenko VA, Shalnova SA, et al. Contribution of cardio-ankle
vascular index to prediction of cardiovascular events in the adult urban population: data from the ESSE-RF study
(Tomsk). Cardiovascular Therapy and Prevention. 2021;20(5):2967. In Russian. (Заирова А.Р., Рогоза А.Н., Ощепко-
ва Е.В., Яровая Е.Б., Куценко В.А., Шальнова С.А. и др. Значение показателя артериальной жесткости «сердечно-
лодыжечный сосудистый индекс – CAVI» для прогноза сердечно-сосудистых событий в популяционной выборке
взрослого городского населения (по материалам исследования ЭССЕ-РФ, Томск) Кардиоваскулярная терапия и
профилактика. 2021;20(5):202-213). doi:10.15829/1728-8800-2021-2967.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 М. В. Ежов, О. А. Погорелова, Б. М. Тамаева, А. Р. Заирова, М. И. Трипотень, И. А. Алексеева, А. Н. Рогоза, Т. В. Балахонова
This work is licensed under a Creative Commons Attribution 4.0 International License.
